PC05.01 Debate 1: Which Is Most Important Efficacy Endpoint in First Line Trials in Advanced NSCLC PFS or OS - Point of View: PFS

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.107
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

MA05.09 PFS and Cardiac-Toxicity-Adjusted-PFS as Predictors of OS in Locally Advanced NSCLC Treated With Concurrent Chemoradiation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

PFS: The Endpoint We Love and Love to Hate

Clinical Cancer Research
Cancer ResearchOncology
2013English

P116 Real World Data of 1st Line A+T in Advanced EGFR+ NSCLC: Clinical Outcome, PFS Influential Factors and Acquired Resistance

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

PC05.04 Debate 2: Patient Reported Outcomes Should Be the Most Important Endpoint in Trials in the Palliative Setting - YES

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

OA07.07 PFS and OS Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-084 Analysis on ALTER0303 Trial: ACECs Level May Correlate With Metastases Burden and Predict PFS of Anlotinib in Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

Alpelisib Extends PFS in PIK3CA-Mutant Breast Cancer

Cancer Discovery
Oncology
2018English

Achievement of VGPR to Induction Therapy Is an Important Prognostic Factor for Longer PFS in the IFM 2005-01 Trial

Blood
BiochemistryImmunologyCell BiologyHematology
2011English

P2.06-26 Ribonucleotide Reductase Subunit M1 but Not M2 Is Associated to Better PFS in Patients With Advanced Stage Mesothelioma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy